Armis Advisers LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Armis Advisers LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,177 shares of the biopharmaceutical company's stock, valued at approximately $295,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after purchasing an additional 200 shares in the last quarter. Baird Financial Group Inc. raised its holdings in Halozyme Therapeutics by 2.0% in the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 221 shares in the last quarter. CreativeOne Wealth LLC raised its holdings in Halozyme Therapeutics by 1.6% in the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after purchasing an additional 294 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock worth $2,279,000 after purchasing an additional 302 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $1.25 during trading hours on Friday, reaching $55.98. The stock had a trading volume of 2,233,873 shares, compared to its average volume of 1,633,884. The stock has a fifty day moving average of $58.91 and a 200 day moving average of $55.67. The stock has a market cap of $6.90 billion, a P/E ratio of 16.32, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Halozyme Therapeutics's revenue for the quarter was up 35.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.79 earnings per share. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares in the company, valued at approximately $1,972,629.59. This represents a 12.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 10,000 shares of company stock worth $597,151 over the last quarter. Insiders own 2.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HALO. HC Wainwright reiterated a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Thursday. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Finally, Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.